Publication: Clinical efficacy of chloroquine versus artemether-lumefantrine for Plasmodium vivax treatment in Thailand.
Issued Date
2007-06-01
Resource Type
ISSN
00234001
Other identifier(s)
2-s2.0-34548107886
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
The Korean journal of parasitology. Vol.45, No.2 (2007), 111-114
Suggested Citation
Srivicha Krudsood, Noppadon Tangpukdee, Sant Muangnoicharoen, Vipa Thanachartwet, Nutthanej Luplertlop, Siripan Srivilairit, Polrat Wilairatana, Shigeyuki Kano, Pascal Ringwald, Sornchai Looareesuwan Clinical efficacy of chloroquine versus artemether-lumefantrine for Plasmodium vivax treatment in Thailand.. The Korean journal of parasitology. Vol.45, No.2 (2007), 111-114. doi:10.3347/kjp.2007.45.2.111 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/24537
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Clinical efficacy of chloroquine versus artemether-lumefantrine for Plasmodium vivax treatment in Thailand.
Other Contributor(s)
Abstract
Chloroquine remains the drug of choice for the treatment of vivax malaria in Thailand. Mixed infections of falciparum and vivax malaria are also common in South-East Asia. Laboratory confirmation of malaria species is not generally available. This study aimed to find alternative regimens for treating both malaria species by using falciparum antimalarial drugs. From June 2004 to May 2005, 98 patients with Plasmodium vivax were randomly treated with either artemether-lumefantrine (n = 47) or chloroquine (n = 51). Both treatments were followed by 15 mg of primaquine over 14 days. Adverse events and clinical and parasitological outcomes were recorded and revealed similar in both groups. The cure rate was 97.4% for the artemether-lumefantrine treated group and 100% for the chloroquine treated group. We concluded that the combination of artemether-lumefantrine and primaquine was well tolerated, as effective as chloroquine and primaquine, and can be an alternative regimen for treatment of vivax malaria especially in the event that a mixed infection of falciparum and vivax malaria could not be ruled out.